<DOC>
	<DOCNO>NCT02625623</DOCNO>
	<brief_summary>The purpose study demonstrate superiority treatment avelumab plus best supportive care ( BSC ) versus physician 's choice ( choose pre-specified list therapeutic option ) plus BSC .</brief_summary>
	<brief_title>Avelumab Third-Line Gastric Cancer ( JAVELIN Gastric 300 )</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Male female subject age great equal ( &gt; = ) 18 year Subjects histologically confirm recurrent unresectable , recurrent locally advanced metastatic adenocarcinoma stomach gastroesophageal junction ( GEJ ) Availability formalinfixed , paraffinembedded ( FFPE ) block contain tumor tissue Subjects must receive 2 prior course systemic treatment unresectable , recurrent , locally advanced metastatic gastric cancer , must progress second line Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 trial entry Adequate hematological , hepatic renal function define protocol Negative blood pregnancy test Screening woman childbearing potential . Highly effective contraception male female subject risk conception exist Other protocol define inclusion criterion could apply Prior therapy antibody drug target Tcell coregulatory protein Concurrent anticancer treatment Major surgery Subjects receive immunosuppressive agent ( steroid ) reason taper drug initiation trial treatment ( exception subject adrenal insufficiency , may continue corticosteroid physiologic replacement dose , equivalent less [ &lt; ] 10 mg prednisone daily ) . All subject brain metastasis , except meet follow criterion : . Brain metastasis treat locally , b . No ongoing neurological symptom relate brain localization disease ( sequelae consequence treatment brain metastasis acceptable ) Previous malignant disease ( gastric cancer ) within last 5 year exception basal squamous cell carcinoma skin carcinoma situ ( bladder , cervical , colorectal , breast ) Prior organ transplantation , include allogeneic stemcell transplantation Significant acute chronic infection Active autoimmune disease might deteriorate receive immunostimulatory agent Known severe hypersensitivity reaction monoclonal antibody , history anaphylaxis , uncontrolled asthma ( , 3 feature partially control asthma ) Persisting toxicity grade &gt; 2 relate prior therapy except alopecia Neuropathy Grade great equal ( &gt; = ) 3 . Pregnancy lactation Known alcohol drug abuse History uncontrolled intercurrent illness include hypertension , active infection , diabetes Clinically significant ( i.e. , active ) cardiovascular disease All significant disease might impair subject 's tolerance trial treatment Any psychiatric condition would prohibit understanding rendering informed consent would limit compliance study requirement Vaccination within 4 week first dose avelumab trial prohibit except administration inactivate vaccine Legal incapacity limit legal capacity Subjects exclude treatment irinotecan paclitaxel monotherapy administration chemotherapy would inconsistent current local labeling ( example , regard contraindication , warnings/precautions , special provision ) chemotherapy . Investigators check updated labeling via relevant website randomization Subjects start treatment administration within 28 day sign informed consent form ( ICF ) . Treatment administration start within 4 day randomization call</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Avelumab</keyword>
	<keyword>Gastric cancer</keyword>
	<keyword>Gastroesophageal junction adenocarcinoma</keyword>
</DOC>